Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen

Viral Immunology

Volumn 20, Issue 1, 2007, Pages 131-141

  Hazra, Rohan ^a,f   Jankelevich, Shirley ^a,b   Mackall, Crystal L ^a   Avila, Nilo A ^c   Wolters, Pamela ^a,d   Civitello, Lucy ^a,e   Christensen, Barbara ^a   Jacobsen, Freda ^a   Steinberg, Seth M ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOUTH CAROLINA DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Medical Illness Counseling Center   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; DIDANOSINE; IMMUNOGLOBULIN; L SELECTIN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER T CELL; NEUROIMAGING; ORGAN SIZE; PROSPECTIVE STUDY; SCHOOL CHILD; THYMUS; VIRUS LOAD;

ADOLESCENT; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; INTELLIGENCE; MALE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34247268312     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.0079     Document Type: Article

References (38)

1. Barnhart HX, Caldwell MB, Thomas P, Mascola L, Ortiz I, Hsu HW, et al.: Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996;97:710-716.
2. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR III, et al.: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-1528.
3. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
4. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998;4:208-214.
5. + T lymphocytes in children on highly active antiretroviral therapy: Dutch Study Group for Children with HIV Infections. AIDS 1998;12:2155-2159.
6. Sleasman JW, Nelson RP, Goodenow MM, Wilfret D, Hutson A, Baseler M, et al.: Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr 1999;134:597-606.
7. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al.: Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999;13:2523-2532.
8. Berkelhamer S, Borock E, Elsen C, Englund J, and Johnson D: Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001;32:1090-1094.
9. Chougnet C, Jankelevich S, Fowke K, Liewehr D, Steinberg SM, Mueller BU, et al.: Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. J Infect Dis 2001;184:201-205.
10. Centers for Disease Control and Prevention: Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
11. Centers for Disease Control and Prevention: Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994;43:1-19.
12. Blazevic V, Jankelevich S, Steinberg SM, Jacobsen F, Yarchoan R, and Shearer GM. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: Analysis of cellular immune responses. Clin Diagn Lab Immunol 2001;8:943-948.
13. Wechsler D: Wechsler Intelligence Scale for Children, 3rd ed. Psychological Corporation, San Antonio, TX, 1991.
14. Wechsler D: Wechsler Adult Intelligence Scale, 3rd ed. Psychological Corporation, San Antonio, TX, 1997.
15. DeCarli C, Civitello LA, Brouwers P, and Pizzo PA: The prevalence of computed tomographic abnormalities of the cerebrum in 100 consecutive children symptomatic with the human immune deficiency virus. Ann Neurol 1993;34: 198-205.
16. Wolters PL, and Brouwers P: Neurobehavioral function and assessment of children and adolescents with HIV-1 infection. In: Textbook of Pediatric HIV Care (Zeichner SL, and Read JS, eds.). Cambridge University Press, Cambridge, 2005.
17. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al.: Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000;355:1875-1881.
18. Tamula MA, Wolters PL, Walsek C, Zeichner S, and Civitello L: Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics 2003;112:679-684.
19. Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, et al.: Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis 2001;183:1116-1120.
20. + T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol 2000;119:493-498.
21. Resino S, Galan I, Perez A, Leon JA, Seoane E, Gurbindo D, et al.: HIV-infected children with moderate/severe immune-suppression: Changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004;137:570-577.
22. + T cells from HIV-infected persons. J Immunol 1994;153:412-420.
23. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, and Egeland T: Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: Functional and clinical correlations. J Infect Dis 1994;169:730-738.
24. L. Immunity 1995;3:87-98.
25. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M, et al.: Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001;97:1458-1466.
26. Vigano A, Vella S, Saresella M, Vanzulli A, Bricalli D, Di Fabio S, et al.: Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000;14:251-261.
27. Clerici M, Saresella M, Trabattoni D, Ferrante P, Vanzulli A, and Vigano A: Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2002;16:2219-2221.
28. Ometto L, De Forni D, Patiri F, Trouplin V, Mammano F, Giacomet V, et al.: Immune reconstitution in HIV-1-infected children on antiretroviral therapy: Role of thymic output and viral fitness. AIDS 2002;16:839-849.
29. Lee JC, Boechat MI, Belzer M, Church JA, De Ville J, Nielsen K, et al.: Thymic volume, T-cell populations, and parameters of thymopoiesis in adolescent and adult survivors of HIV infection acquired in infancy. AIDS 2006; 20:667-674.
30. 2 HIV Study Group. J Allergy Clin Immunol 2000;106:559-566.
31. Douglas SD, Durako SJ, Tustin NB, Houser J, Muenz L, Starr SE, et al.: Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses 2001;17:543-552.
32. Yarchoan R, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, et al.: Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987;1:132-135.
33. Klecker RW Jr, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, et al.: Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-412.
34. Pizzo P, Eddy J, Falloon J, Balis F, Murphy R, Moss H, et al.: Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-896.
35. Brouwers P, Moss HA, Wolters PL, Eddy J, Balis F, Poplack DG, et al.: Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990;117:980-985.
36. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, and Kuijpers TW: Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006;117:e528-e536.
37. Obaro SK, Pugatch D, and Luzuriaga K: Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004;4:510-518.
38. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, et al.: HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005;174:7524-7530.